Results 11 to 20 of about 64,427 (282)
PLoS ONE, 2014 Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin +7 more
doaj +2 more sources
Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet. [PDF]
PLoS ONE, 2015 Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent ...
Ali Kadivar +7 more
doaj +2 more sources
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors [PDF]
New England Journal of Medicine, 2002 BACKGROUND Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical
George D. Demetri +20 more
openalex +2 more sources
Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
Turkish Journal of Hematology, 2016 INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM
Olga Meltem Akay +2 more
doaj +2 more sources
Periorbital edema secondary to imatinib mesylate
Clinical Ophthalmology, 2010 Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland +2 more
doaj +6 more sources
Imatinib mesylate resistance and mutations: An Indian experience
Indian Journal of Medical and Paediatric Oncology, 2013 AbstractThe treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule selective kinase inhibitor imatinib mesylate. Imanitib was the first BCR-ABL targeted agent approved for the treatment of CML patients and confers significant response in most patients; however, a substantial number of patients are initially refractory
Sarjana Dutt, Shweta Srivastava
openaire +5 more sources
The teratogenic effects of imatinib mesylate on rat fetuses
Toxicology Reports, 2015 Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors.
M.M. El Gendy +3 more
doaj +3 more sources
Erythema following imatinib mesylate [PDF]
British Journal of Haematology, 2003 Edward Duncan, Kavita Raj, Ghulam Mufti
openalex +4 more sources
Imatinib mesylate in chordoma [PDF]
Cancer, 2004 AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Paolo G. Casali +17 more
openalex +4 more sources
Imatinib Mesylate and Gray Hair [PDF]
New England Journal of Medicine, 2002 To the Editor: The impressive effects of the tyrosine kinase inhibitor STI571 (imatinib mesylate) in chronic myeloid leukemia were confirmed in the large trial by Kantarjian et al. (Feb. 28 issue).1 We would like to report a new side effect of the drug.
Gabriel Étienne +2 more
openalex +3 more sources